Under the multiyear agreement, Compugen scientists based at the company's research and development facility in Israel will have access to a single information management platform. The tools enable gathering, analyzing, and visualizing project data.

Compugen will have access to Dotmatics' software as a service (SaaS) technology including bioregister, inventory, studies notebook, and platform applications, which may contribute to identifying novel immuno-oncology drug targets and biomarkers.

Dotmatrics technology will replace Compugen's current laboratory information management system (LIMS) and electronic lab notebook (ELN).

Compugen, AstraZeneca reach 1st milestone in deal
Compugen announced it is entitled to receive $2 million upon reaching the first preclinical milestone in an ongoing license agreement with AstraZeneca...